The journey to effectively treating hair loss has seen significant advancements, with the development of new therapies that have revolutionized how we address alopecia. From the early pharmaceutical solutions like Propecia™ and Rogain™ to the groundbreaking introduction of mesotherapy, the evolution of hair loss treatments has been transformative.
Today, AesMed’s AGF39™ Cytokines Therapy stands as the third major evolution in the history of alopecia treatment, offering a cutting-edge approach that is changing the way we fight hair loss.
The First Evolution: Pharmaceutical Treatments
In 1997, Propecia™ and Rogain™ hit the market, marking the beginning of medical hair loss treatment. These treatments focused primarily on inhibiting the production of DHT (Dihydrotestosterone), the hormone responsible for hair follicle shrinkage in cases of androgenetic alopecia (male and female pattern baldness). While these medications proved somewhat effective, they often came with unwanted side effects and did not always deliver permanent solutions for hair regrowth.
The Second Evolution: Mesotherapy for Hair Loss
Around 2003, a new form of treatment emerged—mesotherapy. This technique involves delivering a combination of active ingredients, such as biotin, taurine, and zinc biloba, directly into the scalp. This localized treatment was a significant advancement, as it provided a more targeted approach to treating hair loss. In the early years, mesotherapy was not widely available, and the formulations used often included multi-nutrient prescriptions that targeted the TCA cycle (cellular metabolism). Though effective, the treatments primarily focused on general scalp health and did not fully address the underlying causes of hair loss.
The Third Evolution: AGF39 Cytokines Therapy for Alopecia
In 2007, the understanding of hair loss mechanisms took a new turn with the discovery that cytokines—proteins secreted by DHT—played a central role in the process. These cytokines trigger hair follicle apoptosis (cell death), leading to hair loss. Traditional methods of DHT inhibition, such as finasteride, risked systemic side effects by blocking DHT production in the entire body. A new, localized approach was needed, and this is where cytokines therapy, especially AesMed’s AGF39™, entered the scene.
AGF39™ is a cytokine-based mesotherapy solution designed to target the root causes of hair loss. By using a combination of seven powerful cytokines—KGF, IGF-1, VEGF, bFGF, Noggin, FGF9, and SOD—AGF39™ effectively neutralizes the harmful cytokines produced by DHT at the site of hair follicles. This breakthrough allows for hair follicle regeneration and activation without the need for systemic treatment. AGF39™ not only prevents the apoptosis caused by DHT but also stimulates hair regrowth by activating the necessary growth signals in the hair follicles.
AesMed’s AGF39™: The Gold Standard in Mesotherapy
Since the launch of AGF39™ in 2008, AesMed has continuously refined and improved its formulation, resulting in a product that has become the gold standard in mesotherapy for hair loss treatment. Over the past 18 years, more than 5 million procedures have been performed using AGF39™, making it one of the most popular and widely used treatments for hair loss in South Korea, Japan, China, Turkey, and Malaysia.
The effectiveness of AGF39™ has been demonstrated in clinical trials conducted at two university medical centers, with results published in respected journals like the Journal of Dermatology and presented at the World Congress of Hair Research in 2013 and 2014. These trials confirmed that AGF39™ significantly improves hair density and thickness, providing visible results in as little as two weeks.
Why AGF39™ Is Leading the Way
AesMed’s AGF39™ has transformed the way we approach hair restoration. Its cytokine-based formula not only addresses the underlying causes of hair loss but also stimulates healthy hair growth by rejuvenating the scalp and activating dormant hair follicles. Here are some key benefits of AGF39™:
• Localized treatment:
AGF39™ targets the scalp directly, ensuring that the treatment is both effective and safe without affecting the rest of the body.
• Clinically proven:
Supported by numerous studies and clinical trials, AGF39™ has shown significant improvements in hair growth and scalp health.
• No systemic side effects:
Unlike other treatments that block DHT production in the entire body, AGF39™ works locally, reducing the risk of unwanted side effects.
• Suitable for both men and women:
AGF39™ is effective for treating both male and female pattern baldness, making it a versatile option for a wide range of patients
The Future of Hair Loss Treatment
The third evolution in alopecia treatment has not only redefined the way we approach hair restoration but also opened new possibilities for patients struggling with hair loss.
AesMed’s AGF39™ is a prime example of how innovation in the field of cytokine therapy can offer a more targeted, effective, and safer alternative to traditional treatments.
As more people seek permanent, non-invasive solutions to hair loss, AGF39™ stands at the forefront, setting the standard for mesotherapy and hair regeneration.
If you’re looking for a proven, safe, and effective solution for hair loss, AGF39™ by AesMed may be the breakthrough you’ve been waiting for. Experience the third evolution in alopecia treatment and rediscover the confidence that comes with a fuller, healthier head of hair.
